Index -
P/E -
EPS (ttm) -1.97
Insider Own 5.21%
Shs Outstand 84.88M
Perf Week -10.73%
Market Cap 4.77B
Forward P/E -
EPS next Y -4.05
Insider Trans -3.49%
Shs Float 80.46M
Perf Month -21.96%
Income -153.61M
PEG -
EPS next Q -2.00
Inst Own 66.21%
Short Float 18.34%
Perf Quarter -7.90%
Sales 371.21M
P/S 12.84
EPS this Y -203.50%
Inst Trans -0.04%
Short Ratio 8.29
Perf Half Y 25.33%
Book/sh 23.52
P/B 2.39
EPS next Y 31.22%
ROA -6.87%
Short Interest 14.76M
Perf Year 3.44%
Cash/sh 19.95
P/C 2.81
EPS next 5Y -
ROE -8.17%
52W Range 37.55 - 91.10
Perf YTD -10.29%
Dividend Est. -
P/FCF -
EPS past 5Y 10.83%
ROI -7.29%
52W High -38.35%
Beta 1.78
Dividend TTM -
Quick Ratio 17.54
Sales past 5Y 33402.13%
Gross Margin 65.88%
52W Low 49.56%
ATR (14) 2.83
Dividend Ex-Date -
Current Ratio 17.54
EPS Y/Y TTM 76.72%
Oper. Margin -53.64%
RSI (14) 26.37
Volatility 4.17% 3.64%
Employees 407
Debt/Eq 0.13
Sales Y/Y TTM 30885.48%
Profit Margin -41.38%
Recom 2.21
Target Price 87.61
Option/Short Yes / Yes
LT Debt/Eq 0.12
EPS Q/Q 177.83%
Payout -
Rel Volume 0.98
Prev Close 55.56
Sales Surprise 42.76%
EPS Surprise 1559.13%
Sales Q/Q 3353333.33%
Earnings Feb 21 BMO
Avg Volume 1.78M
Price 56.16
SMA20 -14.39%
SMA50 -23.23%
SMA200 -5.75%
Trades
Volume 1,744,285
Change 1.08%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Dec-11-23 Downgrade
TD Cowen
Market Perform → Underperform
$30
Oct-17-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Sep-27-23 Initiated
Mizuho
Buy
$82
Aug-17-23 Upgrade
Citigroup
Neutral → Buy
May-30-23 Initiated
William Blair
Outperform
$75
Apr-13-23 Initiated
Cantor Fitzgerald
Overweight
$72
Mar-21-23 Initiated
Bernstein
Mkt Perform
$44
Mar-17-23 Initiated
Bryan Garnier
Buy
$70
Mar-07-23 Initiated
Robert W. Baird
Neutral
$46
Oct-11-22 Initiated
Morgan Stanley
Underweight
$37
Aug-09-22 Downgrade
Barclays
Overweight → Equal Weight
$99 → $88
Jun-23-22 Downgrade
Evercore ISI
Outperform → In-line
$66 → $60
Jun-17-22 Initiated
BMO Capital Markets
Outperform
$98
Apr-28-22 Initiated
Credit Suisse
Neutral
$78
Dec-07-21 Initiated
Cowen
Market Perform
Oct-19-21 Initiated
SVB Leerink
Outperform
$126
Jun-14-21 Upgrade
Citigroup
Sell → Neutral
$55 → $132
Apr-21-21 Upgrade
Jefferies
Hold → Buy
$172
Mar-04-21 Initiated
JMP Securities
Mkt Outperform
$160
Show Previous Ratings
Apr-17-24 09:00AM
Apr-16-24 06:00PM
Apr-13-24 08:47AM
Apr-11-24 01:10PM
Apr-10-24 01:46PM
06:00PM
Loading…
Apr-09-24 06:00PM
10:00AM
Apr-05-24 05:03AM
Apr-04-24 06:15PM
Apr-03-24 08:00AM
Apr-01-24 08:00AM
Mar-30-24 06:50AM
Mar-28-24 08:39AM
Mar-27-24 04:50AM
Mar-25-24 06:15PM
10:08AM
Loading…
Mar-24-24 10:08AM
Mar-23-24 06:45AM
Mar-22-24 11:30AM
Mar-21-24 04:19PM
Mar-20-24 01:49PM
Mar-19-24 06:15PM
12:07AM
Mar-17-24 08:50AM
Mar-16-24 08:45AM
Mar-14-24 08:15AM
Mar-13-24 02:25PM
08:30AM
Mar-06-24 02:45PM
Mar-05-24 06:53PM
Mar-04-24 11:02AM
08:48AM
Loading…
08:48AM
Feb-29-24 05:32PM
06:31AM
05:50AM
Feb-27-24 12:00PM
Feb-26-24 08:50AM
06:45AM
Feb-23-24 10:01AM
Feb-22-24 07:37AM
04:00AM
Feb-21-24 04:32PM
(Investor's Business Daily)
10:15AM
(Investor's Business Daily)
07:30AM
Feb-20-24 05:02AM
Feb-19-24 04:08PM
01:45AM
Feb-16-24 02:19PM
07:31AM
Feb-15-24 08:30AM
Feb-14-24 08:15AM
Feb-13-24 01:22PM
(Investor's Business Daily)
10:00AM
08:30AM
02:30AM
Feb-10-24 05:09PM
Feb-09-24 06:00PM
Feb-08-24 02:59AM
Feb-07-24 10:00AM
09:09AM
Feb-05-24 08:00AM
Feb-04-24 02:35PM
Feb-02-24 06:00PM
Feb-01-24 09:10PM
Jan-31-24 12:28PM
Jan-30-24 05:10AM
05:02AM
Jan-28-24 05:10AM
Jan-25-24 06:15PM
08:32AM
Jan-24-24 09:45AM
Jan-23-24 09:30AM
Jan-22-24 09:12AM
05:05AM
Jan-21-24 09:37AM
08:00AM
Jan-20-24 06:50AM
Jan-19-24 06:15PM
Jan-16-24 04:08PM
(Investor's Business Daily)
04:01PM
08:15AM
Jan-15-24 04:56PM
06:30AM
05:19AM
Jan-14-24 01:30PM
05:10AM
Jan-13-24 06:05AM
05:20AM
Jan-10-24 06:00AM
Jan-09-24 06:15PM
Jan-08-24 09:17AM
07:00AM
05:00AM
Jan-06-24 05:00AM
Jan-04-24 05:00AM
Jan-03-24 12:17PM
08:30AM
Jan-01-24 09:05AM
Dec-31-23 10:30AM
08:45AM
Dec-30-23 06:50AM
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kulkarni Samarth Chief Executive Officer Apr 15 '24 Option Exercise 19.12 19,582 374,408 227,704 Apr 17 05:45 PM Kulkarni Samarth Chief Executive Officer Apr 15 '24 Sale 59.91 19,582 1,173,232 208,122 Apr 17 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 15 '24 Option Exercise 19.12 20,000 382,400 228,122 Mar 18 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 15 '24 Sale 72.48 20,000 1,449,628 208,122 Mar 18 05:45 PM Prasad Raju Chief Financial Officer Mar 15 '24 Sale 72.69 3,524 256,160 6,476 Mar 18 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 12 '24 Sale 74.44 4,583 341,159 208,122 Mar 12 05:45 PM KASINGER JAMES R. General Counsel and Secretary Mar 12 '24 Sale 74.44 1,146 85,308 61,174 Mar 12 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 11 '24 Sale 78.26 9,802 767,105 203,705 Mar 12 05:45 PM KASINGER JAMES R. General Counsel and Secretary Mar 11 '24 Sale 78.26 2,801 219,206 60,070 Mar 12 05:45 PM Kulkarni Samarth Chief Executive Officer Feb 20 '24 Sale 79.67 6,370 507,498 194,257 Feb 21 05:45 PM KASINGER JAMES R. General Counsel and Secretary Feb 20 '24 Sale 79.67 1,913 152,409 57,371 Feb 21 05:45 PM Kulkarni Samarth Chief Executive Officer Feb 15 '24 Option Exercise 19.12 20,000 382,400 207,377 Feb 16 05:45 PM Kulkarni Samarth Chief Executive Officer Feb 15 '24 Sale 80.36 20,000 1,607,177 187,377 Feb 16 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 29 '24 Option Exercise 19.12 50,000 956,000 237,377 Jan 31 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 29 '24 Sale 60.51 50,000 3,025,573 187,377 Jan 31 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 16 '24 Option Exercise 19.12 20,000 382,400 207,377 Jan 18 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 16 '24 Sale 62.50 20,000 1,250,058 187,377 Jan 18 05:45 PM Kulkarni Samarth Chief Executive Officer May 30 '23 Option Exercise 19.12 25,000 478,000 412,377 Jun 01 05:44 PM Kulkarni Samarth Chief Executive Officer May 30 '23 Sale 64.88 25,000 1,621,894 387,377 Jun 01 05:44 PM Kulkarni Samarth Chief Executive Officer Apr 25 '23 Option Exercise 19.12 25,000 478,000 412,377 Apr 27 05:37 PM Kulkarni Samarth Chief Executive Officer Apr 25 '23 Sale 50.67 25,000 1,266,638 387,377 Apr 27 05:37 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite